Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman

Join Rahul and Rohit Gosain, the Oncology Brothers, in this insightful podcast episode where they discuss the latest advancements in hematology and oncology. In this episode, they are joined by Dr. Mazyar Shadman from Fred Hutch Cancer Center to delve into the Sequoia and Alpine trials that led to the approval of Zanubrutinib in CLL.

Key Points Discussed:

• The Sequoia trial focused on Zanubrutinib in first-line CLL treatment, showcasing its superiority over traditional chemotherapy.

• The Alpine study compared Zanubrutinib to Ibrutinib in relapsed/refractory settings, demonstrating Zanubrutinib's efficacy and safety profile.

• Acalabrutinib and Zanubrutinib were indirectly compared in a post-analysis, shedding light on their differences.

• Dr. Shadman provides insights on managing common side effects of Zanubrutinib, highlighting its improved tolerability.

Tune in to this episode for a comprehensive discussion on Zanubrutinib in CLL, including trial outcomes, comparisons, and practical considerations for patient care. Stay informed with the Oncology Brothers as they navigate the evolving landscape of oncology treatments